March 12, 2019
Chugai Pharmaceutical said on March 11 that nemolizumab (CIM331), an antibody licensed to Swiss dermatology powerhouse Galderma in the global market, hit the primary endpoint in a PIIb study for the treatment of atopic dermatitis. Galderma presented the final results...read more